Newsroom

Download Announcement ALAMEDA, Calif.–(BUSINESS WIRE)–Dec. 8, 2022– Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from the ongoing dose-escalation stage of QUARTZ-101, a phase 1 clinical trial evaluating XL102, a potent, selective, irreversible and orally bioavailable small molecule cyclindependent kinase 7 (CDK7) inhibitor, in patients with advanced solid tumors. The data are being presented on […]

First oncology early-phase clinical trials units in Portugal and Ireland to offer leading-edge cancer treatments –(BUSINESS WIRE)– SAN ANTONIO–(BUSINESS WIRE)–The START Center for Cancer Care, a San Antonio-based oncology early-phase clinical research site network, will open Portugal’s first facility in Lisbon in late 2022 and is slated to open Ireland’s first early-phase clinical research facility

First oncology early phase clinical trials unit in Portugal to offer leading-edge cancer treatments SAN ANTONIO, Aug. 16, 2022 – The START Center for Cancer Care, a San Antonio-based oncology early-phase clinical research site network, will open Portugal’s first facility in Lisbon in late 2022. START Center’s agreement with Hospital de Santa Maria – Centro

Dr. Drew Rasco is a phase I oncologist here at the START Center for Cancer Care. We interviewed him to try and help patients understand a bit more about what a phase I trial is, why it may be beneficial, and to help try and dispel some of the common myths surrounding phase I studies.